• Internal Medicine
• Medical Oncology
Dr. Bonni Lee Guerin
Hematology & Oncology
• Undergraduate -
• Medical Training - State University of New York, Stonybrook, New York
• Residency - Vanderbilt University, Nashville, Tennessee
• Fellowship - UCSD Cancer Center, San Diego, California
• Awards - Member, Expert Panel Consensus Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma, 2005 & Pfizer Award for Excellence in Biochemical Research, 1983
Bonni L. Guerin, a medical oncologist with 20 years of experience, is dedicated to providing the most up to date, cutting edge treatment while looking at each of her patients as an individual. Her philosophy is one of collaboration, working with all members of the care team to provide the best outcome possible. Dr. Guerin believes that compassion and being a good listener, traits she learned from her mother, help tailor a treatment plan that reflects not only the highest order of medical care, but also one that uniquely reflects each and every patient. Dr. Guerin believes it is just as much about living well as it is living long.
Dr. Guerin currently serves as the Director of Breast Cancer Treatment and Prevention at the Carol G. Simon Cancer Center at Overlook Medical Center. She is the principal investigator of numerous clinical trials exploring new ways to incorporate the latest advances in the management of breast cancer. Dr. Guerin has also served as the Chair, Women's Oncology Forum, Network for Oncology Communication and Research. She has been named by Castle Connelly as one of NY/Metro Top Doctors for the last 8 years, as well as a Top Doctor for Women's Health. She has recently been honored by Curemonos, a New Jersey non-profit organization dedicated to supporting medically underserved women with breast cancer, and was the keynote speaker at the American Cancer Society Relay for Life in Chatham NJ. She is board certified in medical oncology and has advanced specialized expertise in the management of breast diseases. She is also actively involved in the delivery of highly-specialized immunotherapy, IL-2, for the treatment of melanoma and kidney cancer.